US Food and Drug Administration (FDA) has approved delandistrogene moxeparvovecrokl (also known as SRP 9001) for the treatment of ambulatory children (those who are able to walk unassisted) aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene (23 June 2023).
See more details in the document below.
Contact
EAMDA
Linhartova 1
SI-1000 Ljubljana
SLOVENIA
tel: +38614720556
fax: +38614328142
mail: info@eamda.eu
Bank details
IBAN: SI56 0201 1026 2111 086
SWIFT/BIC: LJBASI2X
VAT No.: 64611400
Bank name & address:
Nova Ljubljanska banka d.d.
Trg republike 2
SI-1520 Ljubljana
SLOVENIA